IL131349A - Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors - Google Patents

Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors

Info

Publication number
IL131349A
IL131349A IL13134998A IL13134998A IL131349A IL 131349 A IL131349 A IL 131349A IL 13134998 A IL13134998 A IL 13134998A IL 13134998 A IL13134998 A IL 13134998A IL 131349 A IL131349 A IL 131349A
Authority
IL
Israel
Prior art keywords
group
halofuginone
hydrogen
compound
tumor
Prior art date
Application number
IL13134998A
Other languages
English (en)
Hebrew (he)
Other versions
IL131349A0 (en
Inventor
Nagler Arnon
Pines Mark
Original Assignee
Israel State
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel State, Hadasit Med Res Service filed Critical Israel State
Publication of IL131349A0 publication Critical patent/IL131349A0/xx
Publication of IL131349A publication Critical patent/IL131349A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13134998A 1997-02-11 1998-02-11 Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors IL131349A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/797,703 US6028075A (en) 1997-02-11 1997-02-11 Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
PCT/IL1998/000070 WO1998034613A1 (en) 1997-02-11 1998-02-11 Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Publications (2)

Publication Number Publication Date
IL131349A0 IL131349A0 (en) 2001-03-19
IL131349A true IL131349A (en) 2004-08-31

Family

ID=25171574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13134998A IL131349A (en) 1997-02-11 1998-02-11 Pharmaceuticals containing kinazolinone for the prevention of neovascularization and for the treatment of tumors

Country Status (11)

Country Link
US (3) US6028075A (es)
EP (1) EP1007044B1 (es)
JP (1) JP2001518075A (es)
KR (1) KR100518106B1 (es)
AT (1) ATE367158T1 (es)
AU (1) AU738516B2 (es)
CA (1) CA2280850C (es)
DE (1) DE69838099T2 (es)
ES (1) ES2290983T3 (es)
IL (1) IL131349A (es)
WO (1) WO1998034613A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
EP0991411A4 (en) * 1997-03-31 2000-05-31 Agricultural Res Org TREATMENT OF PULMONARY FIBROSIS
ES2255286T3 (es) * 1998-08-13 2006-06-16 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. Inhibicion de los procesos patogenicos relacionados con las lesiones del tejido.
IL148246A0 (en) * 1999-09-09 2002-09-12 Hadasit Med Res Service Promotion of wound healing
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2002257195A1 (en) * 2001-04-23 2002-11-05 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
ATE469648T1 (de) * 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
WO2003020280A2 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and use thereof in the treatment of cancer
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
WO2004039308A2 (en) * 2002-10-31 2004-05-13 State Of Israel, Ministry Of Agriculture Quinazolinone compositions for regulation of gene expression related to pathological processes
CA2590278A1 (en) * 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
WO2006090376A2 (en) * 2005-02-23 2006-08-31 Collgard Biopharmaceuticals Ltd. Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone
CA2614531C (en) * 2005-07-07 2015-06-16 Avraham Hochberg Nucleic acid agents for downregulating h19, and methods of using same
US20070160640A1 (en) * 2006-01-12 2007-07-12 Eun-Hyun Jang Halofuginone delivering vascular medical devices
WO2007120606A2 (en) * 2006-04-10 2007-10-25 President And Fellows Of Harvard College Methods for modulating formation and progression of cellulite
EP2101834B1 (en) * 2006-12-01 2015-03-25 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
US7928083B2 (en) 2007-01-16 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2008087650A2 (en) * 2007-01-21 2008-07-24 Agricultural Research Organization Composition and method for treating or preventing skeletal muscle fibrosis
BRPI0813355A2 (pt) 2007-06-22 2014-12-30 Arqule Inc Compostos de quinazolinona e métodos de uso dos mesmos
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
CN102177152A (zh) 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
WO2013106702A1 (en) 2012-01-13 2013-07-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
WO2015034330A1 (ko) * 2013-09-09 2015-03-12 가톨릭대학교 산학협력단 헬로퓨지농을 유효성분으로 포함하는 골질환 치료 또는 예방용 조성물
CN105497091B (zh) * 2016-01-05 2020-01-24 香港浸会大学 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation PROLYL-ARNT-SYNTHETASE INHIBITORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) * 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Also Published As

Publication number Publication date
US6028075A (en) 2000-02-22
EP1007044A4 (en) 2001-03-07
EP1007044A1 (en) 2000-06-14
DE69838099D1 (de) 2007-08-30
AU738516B2 (en) 2001-09-20
DE69838099T2 (de) 2008-04-30
US6420371B1 (en) 2002-07-16
KR100518106B1 (ko) 2005-10-04
USRE39574E1 (en) 2007-04-17
KR20000070996A (ko) 2000-11-25
EP1007044B1 (en) 2007-07-18
IL131349A0 (en) 2001-03-19
CA2280850A1 (en) 1998-08-13
ATE367158T1 (de) 2007-08-15
CA2280850C (en) 2004-01-13
JP2001518075A (ja) 2001-10-09
AU6004998A (en) 1998-08-26
WO1998034613A1 (en) 1998-08-13
ES2290983T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
EP1007044B1 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
Joussen et al. Inhibition of inflammatory corneal angiogenesis by TNP-470
AU705955B2 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
KR101644440B1 (ko) 개선된 혈관신생 억제용 펩티드와 이를 유효성분으로 함유하는 혈관신생과 관련된 질환의 예방 및 치료용 조성물
US6090814A (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6211188B1 (en) Treatment of skin disorders
KR20210020849A (ko) 크리소파놀을 포함하는 난소암 또는 유방암의 예방 또는 치료용 약학적 조성물
KR100450578B1 (ko) 엔엠23 단백질을 유효성분으로 하는, 매트릭스메탈로프로테아제 활성 억제 및 혈관신생 억제용 조성물
EP0794780B1 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
AU2007335963A1 (en) Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature
KR20210062449A (ko) 프리마퀸 디포스페이트와 그 타겟으로 usp1의 혈관누수차단 효과
US7709538B2 (en) ST104P, an anti-angiogenic agent
WO2002051423A1 (fr) Inhibiteurs d'angiogénèse
WO2005009461A1 (en) Factor vii activating protease (fsap) polypeptides for the treatment of angiogenesis-related disorders
KR20020045821A (ko) 히스톤 디아세틸라제 억제 및 암 전이 억제 효과와 항염증 효과를 나타내는 아피시딘 유도체, 이를 포함하는 약학적 조성물 및 그의 용도

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees